Retrospective study of a cohort of adult patients with hematological malignancies in a tropical area

Table 2 Characteristics, treatment and evolution of 22 patients with active multiple

No.	Gender	Age	Ig	Stage	Regimen 1	Regimen 2	Regimen 3	FU (yr)
1	M	65	IgAλ	IIIB	Bortezomib + DEXA	Melphalan DEXA	0	6
2	F	60	IgGκ	NA	Bortezomib + DEXA	0	0	3
3	M	66	IgAκ	NA	Bortezomib + DEXA	0	0	< 1
4	F	77	IgAκ	IIIB	Thalidomide + Melphalan	Melphalan + DEXA	0	< 1
5	F	80	NA	IIIA	Thalidomide	0	0	< 1
6	M	56	IgAκ	IIIB	Thalidomide + DEXA	Thalidomide + Melphalan	0	2
7	F	71	IgGκ	NA	Bortezomib + DEXA	Thalidomide	0	4
8	F	85	IgGκ	IA	Melphalan + DEXA	0	0	6
9	F	62	IgAλ	NA	Melphalan + DEXA	Bortezomib + DEXA	0	7+
10	M	83	NA	NA	NA	0	0	< 1
11	F	65	IgGλ	IIIA	Bortezomib + DEXA Thalidomide	VAD	0	11
12	F	81	NA	IIIB	Thalidomide + Melphalan + DEXA	0	0	< 1
13	M	57	IgGκ	NA	Bortezomib	0	0	6
14	F	69	IgGκ	IIIA	Melphalan + Thalidomide,	Lenalidomide	0	4
15	F	59	IgGκ	IIIA	Bortezomib + DEXA + Thalidomide	HDCT	0	3+
16	M	44	IgAκ	IIIB	Bortezomib + DEXA	HDCT	0	3
17	F	60	IgGκ	IIIB	DEXA+ Melphalan + Thalidomide	HDCT	Lenalidomide	6
18	M	52	IgGλ	IIIA	Bortezomib + DEXA	HDCT	0	2
19	F	61	IgGκ	IIIB	Bortezomib + DEXA + Thalidomide	HDCT	0	2
20	M	62	NA	NA	Bortezomib + DEXA	HDCT	Lenalidomide	2
21	M	53	IgAκ	IIIA	VAD	HDCT	0	12
22	F	55	IgGκ	IIIA	Bortezomib + DEXA + Thalidomide	HDCT	0	< 1

M: Male; F: Female; age in years; stage according to Durie-Salmon; Ig: Immunoglobulin; FU: Follow-up (+: died); DEXA: Dexamethasone; HDCT: High-dose chemotherapy; VAD: Vincristine, adriamycine, dexamethasone; NA: Not available.